Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLYMPIA-5: odronextamab + lenalidomide versus rituximab + lenalidomide in relapsed/refractory follicular lymphoma or marginal zone lymphoma
MOH_2023-10-18_012994Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of odronextamab in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary endpoint not reported. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
odronextamab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on MOH_2023-10-18_012994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-18_012994.